



2011 Annual Report





Contents

Chairman's Report	4
CEO's Report	5
Directors' Report	9
Corporate Governance	25
Financial Report	29
Additional Information	67
Corporate Directory	68

Cellmid Limited (ASX:CDY)
Annual Financial Report

ABN 69 111 304 119

Level 6
40 King Street
Sydney NSW 2000
Australia

T: +61 2 9299 0311
F: +61 2 9299 2198

E: info@cellmid.com.au
W: www.cellmid.com.au

Chairman's Report



Dear Shareholder,

I am pleased to present to you the 2011 Annual Report of Cellmid Limited.

I am also pleased to report that the Company has continued to build successfully on the important programs of the previous reporting period, as well as action two significant new initiatives. A lifestyle subsidiary, Advangen International Pty Ltd, was launched late in October 2010, and has international distribution rights for a novel scientifically validated range of hair loss products developed in Japan. Sales results during a test marketing period of this exclusive product range have been pleasing. Importantly, Advangen will provide a valuable sales and operational platform for the introduction of products incorporating our flagship protein midkine (MK), which pre-clinical studies indicate may be effective in the treatment of various forms of hair loss (alopecia).

A second major initiative was the hosting in Sydney in November 2010 of the first ever global meeting of key opinion leaders on midkine. The highly successful conference attracted leading researchers from eleven countries representing a number of therapeutic and diagnostic research fields. Collaborations arising from the conference are opening up new opportunities for value creation from our extensive intellectual property rights around midkine; we are already planning a follow-up conference in 2012.

As foreshadowed in last year's report, the Company completed the development of the first ever fully validated midkine blood test (MK ELISA) during the year. We recently announced that the test kits have now been successfully produced in a GMP compliant environment, which is an important milestone in the full commercialization of midkine as a cancer marker.

Also on the diagnostic front, in May the Company received a report from Celera Corporation in relation to its MK lung cancer diagnostic licence. Celera reported promising results from a study, using their six biomarker lung cancer diagnostic panel including midkine, of patients who never smoked. We look forward with some anticipation to further results under this important licence agreement.

There has also been significant progress in our therapeutic programs. In August 2010, we completed in vivo testing of two of the Company's anti-MK monoclonal antibodies in

animal models of multiple sclerosis, with a reduction in disease severity. In April this year we entered into an important new collaborative agreement with Antitope Limited, of Cambridge (UK), for the humanisation of these lead therapeutic antibody candidates.

Also in April this year, through our collaboration with Pharmahungary, we completed milestone pre-clinical studies into the efficacy of MK for the treatment of acute myocardial infarction, with very encouraging results; important chronic heart disease studies can now commence.

Further details of all these important developments can be found in the report from our CEO and Managing Director Maria Halasz elsewhere in this Annual Report.

As in 2010, the 2011 financial year presented challenging market conditions for Cellmid as for other companies competing for scarce capital from risk-averse markets. We have been able to make pleasing progress and meet significant milestones in all our core programs with the benefit of funding through an equity line of credit. We will continue to husband our financial and human resources so as to achieve our goal of generating sufficient cash flow to fund our outstanding development prospects. Our various on-going collaborative projects and partnerships in Japan continue to provide great value to the Company, and were thankfully largely unaffected by the terrible natural disaster which struck that country earlier in the year.

Although we lost the services of Ko Koike as a director during the year, we are delighted that he continues to work with us in a valuable consulting role from his base in Japan. We have also continued to strengthen our technical team to reflect the diversification of the Company's portfolio of development projects. On behalf of the Board and shareholders I thank our highly motivated Cellmid team of staff and advisers for the year's achievements. I also sincerely thank all our shareholders for their support.

A handwritten signature in dark ink, appearing to read 'D. King'. The signature is fluid and cursive, with a long, sweeping underline.

Dr David King
Chairman



CEO'S Report

Dear Shareholder,

Cellmid reached a number of product development milestones during the 2011 financial year in its diagnostic and therapeutic business units and is well on its way to become a clinical stage company. In addition, the Company has established a new, wholly owned subsidiary, Advangen International Pty Ltd, for the development, manufacture and sale of cosmeceuticals products. Cellmid has become a fundamentally stronger and more asset rich company during the reporting period.

On the financial front the Company signed an agreement with La Jolla Cove investors in September 2010 for up to US\$8M funding by way of a maximum of eight \$1M Convertible Notes. To date the Company has issued two notes of \$1M each to La Jolla Cove. Further issues of Convertible Notes will be subject to separate shareholders' approval.

Cellmid has earned revenues of \$149,735 (2010: \$325,999) from product sales and it recorded a loss of \$2,269,637 (2010: \$1,339,948). In addition to general working capital, and the costs associated with setting up its wholly owned subsidiary Advangen International Pty Ltd, the company's funds have been spent on the completion of the development of the midkine ELISA test, the humanisation of the anti-midkine antibody and the completion of the proof of concept study of the heart attack program.

In December 2010 Mr Ko Koike has resigned from the board but has remained with the Company as a Consultant, providing invaluable support in maintaining and developing Japanese relationships. It has been with great relief that the Company has been able to advise shareholders in March 2011 that all of its associated teams and operations were safe from the devastating earthquake that hit the East coast of Japan.

The Cellmid management team has been boosted with the appointment of Dr Alana Wylie who is expected to manage the Company's in-house diagnostic programs.

PRODUCT DEVELOPMENT

CAB102 Midkine antibody program is on track for phase 1 clinical trials in late 2012

As the first stage of the Company's antibody evaluation program in August 2010 Cellmid completed preclinical testing of its lead mouse monoclonal antibodies CDY91 and CDY92 in an animal model of multiple sclerosis. The results of the independently conducted study have shown decrease in disease severity and significant reduction of inflammatory cell infiltration in the spinal cord. This has been an important finding confirming previous study results and provided valuable information on the antibodies' mechanism of action.




FIGURE 1: Mk ANTIBODY PROGRAM

This timetable is subject to a number of conditions including availability of funding and positive results from preclinical studies.

CEO's Report

Continued

Inflammatory diseases are often driven by infiltration of leucocytes to the site of inflammation where they may cause tissue damage and permanent degenerative conditions. By the administration of the Company's antibodies significant reduction in this harmful process has been observed which in turn represents substantial therapeutic opportunities.

With this solid finding the Company has embarked on a program of selecting a lead mouse monoclonal antibody for humanisation. Assessment on the basis of biological activity inhibiting midkine in vitro and affinity studies resulted in a clear lead candidate in early 2011. With a well performing mouse monoclonal candidate the Company set up a partnership in April 2011 with Antitope in Cambridge, UK, for the humanisation of the antibody. The collaboration resulted in the successful development of a chimeric antibody in June 2011, an important milestone in the program.

Once humanised, the antibody is expected to be tested in a number of disease models where infiltration of inflammatory cells to the site are key to disease development. The Company is currently assessing animal models of acute and chronic kidney disease (AKI and CKD), chronic obstructive pulmonary disease (COPD) and surgical adhesion. All of these diseases inflict significant burden and affect large (and growing) patient populations, and all three areas represent unmet medical needs poorly serviced by existing treatments.

Concurrent to the preclinical testing the Company will commence GMP manufacture of the human antibody in preparation for clinical trials in late 2012.

CAMI103 Midkine for the treatment of heart attack reached proof of concept

Cellmid continued its collaboration with cardiac research group Pharmahungary during the reporting period. This program consists of seven preclinical studies in preparation for human trials of midkine for treating heart attack. Stages 1, 2, 3, 6 and 7 of the studies have been completed since the commencement of the collaboration including an efficacy study which demonstrated that MK reduced infarct size in a rat model of acute myocardial infarct (AMI).

Chronic heart disease studies are planned for early 2012 to demonstrate the long term benefits of administering midkine following heart attack. These studies are expected

to validate previous findings, where a single dose of midkine up to two weeks following heart attack improved cardiac output and prevented ventricular remodelling. GMP manufacture of MK is planned for 2012, along with safety/toxicity testing, clinical trials planning and pre-IND/IND preparation. Phase 1 clinical trials are anticipated to commence in 2013, subject to the outcomes of the chronic and large animal studies.

ELISA – CE Marking is a major upcoming milestone

Elevated blood midkine levels have been detected in 26 different cancers to date and implicated in chronic inflammatory conditions. Midkine has been shown to be superior to most other cancer markers as it detects a higher percentage of cancers and at an earlier stage. Furthermore, midkine adds value at every stage of the diagnostic spectrum from screening to diagnosis, prognosis, treatment monitoring and detecting recurrence of cancer. Midkine, as a cancer biomarker, has to date been the subject of over 50 peer reviewed publications in scientific journals.

Cellmid has a comprehensive program for the clinical validation, regulatory approval and marketing of diagnostic tools using midkine on the basis of this extensive data generated to date. The first step in this program was the development and validation of a highly accurate blood test for the measurement of midkine. The Company completed this milestone in November 2010 with the development of a blood test that measures midkine to a lower limit of 8 pg/ml (eight part per trillion) and a dynamic range of 25-1000 pg/ml.

Following validation Cellmid embarked on scaling up the manufacturing technology and transferring it into a GMP environment in preparation for regulatory approvals. Once manufactured under GMP conditions the test will be submitted for European regulatory approvals (CE Marking) and used in all of Cellmid's internal diagnostic programs. The midkine ELISA is the first product for the research market and represents not only a revenue opportunity but a strong component of commercial partnerships as well.

The Company continues its out-licensing of the midkine diagnostic patent portfolio. Cellmid's first diagnostic license to Celera (Quest Diagnostics) resulted in the reporting of a significant product development milestone in May 2011. Celera released results of its six biomarker panel (one of which is midkine) for the screening of lung cancer amongst

those never smokers presenting with non-specific lung complaints. The test showed 85% sensitivity and 83% specificity at its best performance (see Figure 2 below), and compared well with CT scanning, the current gold standard screening method. Considering the associated risks of CT scans, it is expected that this test will be at least an adjunct screening method.

Performance	Sensitivity	Specificity
Higher Sensitivity	0.95	0.70
Best Overall	0.85	0.83
Higher Specificity	0.68	0.95





FIGURE 2: SIX BIOMARKER PANEL FOR EARLY STAGE LUNG CANCER DETECTION

On further analysis of the data released by Celera in relation to the test, midkine was one of the best performing of the six markers (see Figure 3) confirming other comparative data available on its accuracy. Cellmid's license with Celera includes one additional milestone payment and royalties on products sold.



	Never Smoker		Smoker	
	AUC	P value	AUC	P value
CEA	0.747	0.0001	0.664	<0.0001
CYFRA	0.690	0.0035	0.767	<0.0001
0502	0.917	<0.0001	0.669	<0.0001
0702	0.816	<0.0001	0.711	<0.0001
0451	0.719	0.0008	0.623	0.0002
0879	0.670	0.0090	0.730	<0.0001

FIGURE 3 : COMPARISON OF INDIVIDUAL MARKERS SHOWS MIDKINE AS ONE OF THE BEST PERFORMERS

CEO's Report

Continued

Advangen International Pty Ltd

Cellmid launched Advangen International Pty Ltd (Advangen), its wholly owned subsidiary, in October 2010 for the development, manufacture and sale of life style products, initially for the treatment of various forms of hair loss. Advangen was formed to exploit the significant hair loss market by developing treatments that adhere to strict scientific standards, and therefore create a strong differentiating factor between its range and the majority of products in this segment.

To facilitate the funding of this program Advangen has negotiated exclusive international manufacturing distribution rights for a range of scientifically tested and validated hair loss prevention products recently launched in Japan. The range of FGF-5 inhibitors includes a shampoo (Jo-Ju), and lotion for men (Lexilis) and women (Jo-Ju). Advangen has initially test marketed the products as "cosmetics", with no hair loss prevention claims to assess its use characteristics on the Caucasian quality hair. Essential to marketing, GMP manufacture involves technology transfer and is expected to be completed by the 4Q2011. Once GMP manufactured, Advangen will apply for regulatory approvals and will be able to make appropriate claims in relation to the products' efficacy. Product sales through direct marketing and retail channels is expected to commence after cosmeceutical listing in early 2012.

Excellence in Midkine Research – Inaugural Midkine Conference

Cellmid held the first ever scientific conference on midkine, Excellence in Midkine Research, in November 2010. The conference attracted leading researchers and clinicians from eleven countries representing a number of therapeutic and diagnostic fields.

Invitation was only extended to accomplished scientists in midkine research and to advisers of Cellmid to allow for free exchange of ideas and protection of any new intellectual property. Benefits of the conference have been many-fold for the Company and the collaborations formed are likely to result in the generation of ongoing validation and novel intellectual property relating to midkine.

Cellmid will be holding the next Excellence in Midkine Research Conference in Istanbul, Turkey, in 2012 with co-sponsors Istanbul University and Yeni Yuzyl University. Interest in the conference is expected to increase following the success of the Sydney meeting and this time will be open to selected commercial partners.

Even though the 2011 financial year has been challenging from a macro economic and portfolio perspective the Company has closed a successful period with an improved product portfolio and asset profile.

I would like to thank the Board and the talented Cellmid team for their contribution in achieving these substantial milestones this financial year. I would also like to thank our shareholders for their active support.



Maria Halasz
CEO and Managing Director

Directors' Report

Contents

Directors' Report	9
Auditor's Independence Declaration	23
Corporate Governance	25
Directors' Declaration	64

Your directors present their report, together with the financial statements of the group, being the company and its controlled entity, for the financial year ended 30 June 2011.

Directors

The following persons were directors of Cellmid Limited during the financial year and up to the date of this report:

Dr David King
Ms Maria Halasz
Mr Robin Beaumont
Mr Koichiro Koike (resigned on 10 December 2010)

Principal Activities and Significant Changes in the Nature of Activities

The principal activities of the group during the financial year were;

- the development and commercialisation of diagnostic and therapeutic products for the management of diseases such as cancer and various chronic inflammatory conditions
- the development and sale of treatments to alleviate excessive and abnormal hair loss and re-establish the natural hair growth cycle

There have been no significant changes in the nature of the principal activities of the group during the financial year.

Operating Results and Review of Operations for the Year

The consolidated net loss of the group amounted to \$2,263,410, after providing for income tax, and eliminating non-controlling equity interests. This represents a 69% increase on the results reported for the year ended 30 June 2010. The significant increase was due to the substantial increase in expenditure on research and development and the start-up costs associated with launching Advangen International Pty Ltd.

Directors' Report

Continued

REVIEW OF OPERATIONS

The group has achieved a number of product development objectives in its therapeutic and diagnostic product development programs.

Project ELISA

Elevated blood midkine levels are associated with various cancers and chronic inflammatory diseases. Accurate measurement of midkine in blood is therefore an important tool for the diagnosis, prognosis and treatment monitoring of cancer. Following several years of research the group has successfully completed the development of its proprietary, sensitive, reproducible and fully validated midkine measurement test, the MK-ELISA.

The group's MK-ELISA has a highly accurate lower detection limit of 8 pg/ml (8 parts per trillion) and a clinically significant dynamic range (25pg/ml to 1000 pg/ml). Following the development phase the production of the MK-ELISA was successfully transferred into a GMP (Good Manufacturing Practice) environment. The GMP produced MK-ELISA systems are expected to be sold to researchers and used in the group's in-house diagnostic validation programs.

Completion of the MK-ELISA development and GMP manufacture represents a significant milestone in the commercialisation of the group's diagnostic intellectual property assets.

Project CAN104

The group has completed collection of symptom-free dog serum samples to be used for establishing midkine levels in healthy dogs. Testing of the samples will be carried out using the GMP manufactured ELISA kits. In addition, collection of serum samples from cancer bearing dogs has also commenced although it has been slower than expected. The group expects to accelerate this process in the future through partnership with a large veterinary company. The trials are expected to evaluate midkine for the early diagnosis of the most common cancer types in dogs including mammary carcinoma, hemangiosarcoma, osteosarcoma and specified skin tumours, mast cell tumours, melanomas and squamous cell carcinomas, comparing the midkine levels in cancer bearing dog sera to that of healthy animals.

Project CK3000

As part of its cancer screening program the group has continued the CK3000 Project with the collection of 400 healthy individual's serum samples. Although the project has been established for the testing of up to 3,000 healthy samples, before further collection, the group will test the initial 400 serum samples with the GMP manufactured MK-ELISA. Once the data generated from the study is assessed it will provide clarity as to the necessity for further collection and testing. In the event that the testing will yield statistically relevant results it may be sufficient to use only the existing 400 serum samples to demonstrate healthy midkine levels as part of a future regulatory submission.

Project CS5000

This project will continue immediately after completion of the testing of healthy samples with the collection of serum from individuals diagnosed with certain cancers. The collection process is expected to take up to two years and in relation to each individual will involve blood collection at the time of diagnosis, following treatment and quarterly during recovery for up to one year. This is a multicentre study involving the assessment of several cancer types and in hospitals in Australia, Turkey and Japan.

Advances in therapeutic product development

The group has two therapeutic programs, CAMI103 and CAB101, in pre-clinical stage. The group has advanced both programs during the period with the completion of substantial product development milestones.

CAMI103

Under this program the group is developing the midkine protein for the treatment of heart muscle damage following a heart attack (AMI). The CAMI103 development program is a series of preclinical studies from Stage 1 to Stage 7. During the reporting period the group has successfully completed Stages 1, 2, 3 and 7. The studies so far have demonstrated midkine's strong cardioprotective characteristics in vitro and in vivo. The group has also commenced Stage 4, a chronic study evaluating the long term benefits of administration of midkine following heart attack.

CAB103

This program is aimed to develop the first ever humanised anti-midkine antibody for the treatment of a range of inflammatory and autoimmune diseases. The program commenced with the pre-clinical testing of mouse monoclonal antibodies in inflammatory disease models, which resulted in the selection of potential lead candidates for humanisation on the basis of their in vivo biological activity. The lead candidates have been further evaluated for binding efficiency to midkine and a lead candidate was selected earlier in the reporting period for humanisation.

The group commenced the antibody engineering process and completed the development of a chimeric anti-midkine antibody. Successful development of a chimeric antibody with similar binding characteristics to the original mouse anti-midkine antibody was a major milestone in the CAB101 program during reporting period and reduced the technical risk of successfully engineering a humanised drug candidate. Completion of the humanisation program is expected to continue on schedule. Following humanisation, the antibody will be produced and tested in a number of inflammatory disease models.

Advangen International Pty Ltd (Advangen)

Advangen has been set up to exploit the company's midkine intellectual property for hair growth, as well as to develop, manufacture and sell additional products aimed at the hair health market. The assets of the group have been significantly boosted during the reporting period by building the Advangen business, which currently has two product lines, one in development (MK for hair) and the other one market ready (FGF-5 inhibitors).

During the reporting period the group has become the sole distributor for the FGF-5 inhibitor product range globally, other than Japan, China, South Korea and Taiwan. Furthermore, the group has been able to secure manufacturing rights and commenced preparation for Australian manufacture, TGA (Therapeutic Goods Administration) listing and marketing of this product range. The products are currently available for purchase on www.advangen.com.au, including shampoo and lotions for men and women to optimise hair health, prevent hair loss and maximise hair growth potential. Marketing claims at this stage are limited to cosmetic use and will remain so until approval for listing is granted by the TGA.

The group's patent application for the use of midkine for hair growth has entered the provisional phase during the period. Pre-clinical, toxicity and clinical studies are planned to begin late in calendar 2012 following the GMP manufacture of midkine.

Financial Position

The net assets of the consolidated group decreased from \$2,848,939 to \$2,037,968 between 30 June 2010 and 30 June 2011. This decrease is due to operating losses, but is offset by proceeds from share issues raising \$1,193,771. The directors believe that the group is in a stable financial position to expand and grow its current operations.

Significant Changes in the State of Affairs

During the reporting period, the group has launched its wholly owned subsidiary, Advangen International Pty Ltd, for the manufacture and sale of hair growth and hair cycle extension products. The details of changes were mentioned above under the heading "Advangen International Pty Ltd (Advangen)"

Directors' Report

Continued

Dividends Paid or Recommended

The company has not paid or declared any dividends during the financial year.

Events after the Reporting Period

There have been no matters or circumstances which have arisen since the end of the financial year which significantly affected or could significantly affect the operations of the group, the results of those operations, or the state of affairs of the group in the future years.

Future Developments, Prospects and Business Strategies

Likely developments, future prospects and business strategies of the operations of the group and the expected results of those operations have not been included in this report as the directors believe, on reasonable grounds, that the inclusion of such information could result in unreasonable prejudice to the consolidated group.

Environmental Issues

The group's operations are not subject to significant environmental regulations under the laws of the Commonwealth and the state.

Board and Audit Committee meetings

The number of meetings of directors held during the year and the number of meetings attended by each director were as follows:

	Board meetings		Audit Committee meetings		Remuneration meetings	
	Number eligible to attend	Number attended	Number eligible to attend	Number attended	Number eligible to attend	Number attended
Ms Maria Halasz **	6	6	-	-	-	-
Mr Koiche Koike	3	3	-	-	-	-
Dr David King	6	6	5	5	1	1
Mr Robin Beaumont	6	6	5	5	1	1

The Nomination Committee of the board met on several occasions during the financial year on an informal basis.

** Attends the Audit Committee meeting by invitation.

Information on Directors

David King

Chair (Non-executive)

Qualifications

Fellow of The Australian Institute of Company Directors, Fellow of the Australian Institute of Geoscientists and a PHD in Seismology from the Australian National University.

Experience

Experience in high growth companies and a track record in starting business ventures and developing them into attractive investment and/or take-over targets.

Interest in Shares and Options

Shares: 13,476,669, indirectly held.

Special Responsibilities

A member of the Audit Committee, and Remuneration Committee

Directorships held in other listed entities during the three years prior to the current year

Current directorships - Robust Resources Limited, Eastern Star Gas Limited and Republic Gold Limited.

Previous directorship - Gas2Grid Limited and Ausmon Resources Limited and Sapex Limited.

Maria Halasz

Managing Director (Executive)

Qualifications

A Graduate of the Australian Institute of Company Directors; BSc degree in microbiology and an MBA.

Experience

Over 18 years experience in biotechnology companies; initially working in executive positions in biotechnology firms, then managing investment funds and later holding senior positions in corporate finance specialising in life sciences

Interest in Shares and Options

Shares: 1,365,000 indirectly held

Options: 2,000,000 (Expiry: 16 April 2013, exercisable at 0.05735 each) Directly held, 3,000,000 (Expiry: 03 July 2013, exercisable at 0.05735 each), 7,000,000 (Expiry: 20 November 2014, exercisable at 0.056) Directly held

Special Responsibilities

Managing Director and Chief Executive Officer

Directors' Report

Continued

Directorships held in other listed entities during the three years prior to the current year

None

Robin Beaumont

Director - Non-Executive

Experience

Senior strategic adviser and experienced public company director, several years experience in biotechnology companies.

Interest in Shares and Options

Shares: 700,000 shares indirectly held

Special Responsibilities

Chairman of the Audit Committee, and a member of the Remuneration Committee

Directorships held in other listed entities during the three years prior to the current year

Steelbro Group Limited, Evogenix Ltd, Arana Therapeutics Ltd and Select Vaccines Ltd.

Remuneration report

The information provided in this remuneration report has been audited as required by section 308 (3C) of the Corporations Act 2001.

The remuneration report is set out under the following main headings:

- A. Principles used to determine the nature and amount of remuneration
- B. Details of remuneration
- C. Service agreements
- D. Share-based compensation
- E. Additional information

A. Principles used to determine the nature and amount of remuneration

The performance of the group depends on the quality of its directors and executives.

To prosper, the group must attract, motivate and retain highly skilled directors and executives. To this end, the group embodies the following principles in its remuneration framework:

- provide competitive rewards to attract high calibre executives
- establish appropriate performance hurdles in relation to variable executive remuneration.

The Board of Directors assesses the appropriateness of the nature and amount of remuneration of directors and senior managers on a periodic basis by reference to relevant employment market conditions with the overall objective of ensuring maximum stakeholder benefit from the retention of a high quality Board and executive team.

Remuneration structure

In accordance with best practice corporate governance, the structure of non-executive director and senior manager remuneration is separate and distinct.

Non-executive director remuneration

Objective

The Board seeks to set aggregate remuneration at a level that provides the group with the ability to attract and retain directors of the highest calibre, while incurring costs that are acceptable to shareholders.

Structure

Each non-executive director receives a fixed fee for being a director of the group.

The constitution and the ASX listing rules specify that the maximum aggregate remuneration of non-executive directors shall be determined from time to time by a general meeting of shareholders. At the general meeting of shareholders in 2005, the maximum amount set at \$300,000 per annum. In 2011, the group paid non-executive directors a total of \$153,751 (2010: (\$186,869).

The amount of aggregate remuneration sought to be approved by shareholders and the fixed fees paid to directors are reviewed annually. The Board considers fees paid to non-executive directors of comparable companies when undertaking the annual review process.

Executive remuneration

Objective

The group aims to reward executives with a level and mix of remuneration commensurate with their position and responsibilities within the group and so as to:

- reward executives for group and individual performance against targets set by reference to appropriate benchmarks
- align the interests of executives with those of shareholders
- ensure total remuneration is competitive by market standards.

Structure

A policy of the Board is the establishment of employment or consulting contracts with the CEO and other senior executives. Remuneration consists of fixed remuneration under an employment or consultancy agreement and long term equity-based incentives that are subject to satisfaction of performance conditions. The equity-based incentives are intended to retain key executives and reward performance against agreed performance objectives.

Fixed remuneration

The level of fixed remuneration is set so as to provide a base level of remuneration that is both appropriate to the position and competitive in the market.

Fixed remuneration is reviewed annually by the Board and the process consists of a review of group-wide and individual performance, relevant comparative remuneration in the market, and internal and (where appropriate) external advice on policies and practices.

Senior managers are given the opportunity to receive their fixed (primary) remuneration in a variety of forms including cash and expense payment plans, such that the manner of payment chosen is optimal for the recipient without creating additional cost for the group.

Directors' Report

Continued

Remuneration policy and performance

Other than the CEO, Ms Halasz, none of the Director's remuneration is 'at risk' remuneration. Refer page 18 for further information on Ms Halasz's remuneration.

B. Details of remuneration (audited)

Details of the remuneration of the directors and key management personnel of the group (as defined in AASB 124 Related Party Disclosures) and the highest paid executives of Cellmid Limited are set out in the following tables.

2011

Name	Short-term benefits			Post employment Benefits		Share-based payment	Total
	Cash salary and fees	Cash bonus	Non-monetary benefits	Super-annuation	Retirement benefits	Options	
	\$	\$	\$	\$	\$	\$	\$
<i>Non-executive directors</i>							
David King (Chairman)	65,000	-	-	5,850	-	-	70,850
Robin Beaumont ⁴	30,000	-	-	-	-	-	30,000
Koichiro Koike ¹	52,901	-	-	-	-	-	52,901
Total non-executive directors	147,001	-	-	5,850	-	-	153,751
Executive directors and key Management							
Maria Halasz	358,333	-	-	32,250	-	-	390,583
Nicholas Falzon ²	-	-	-	-	-	-	-
Andrew Bursill ³	-	-	-	-	-	-	-
Total Executive directors and key Management	358,333	-	-	32,250	-	-	390,583
Total	505,334	-	-	38,100	-	-	544,334

¹ Koichiro Koike resigned on December 2010. The remuneration as a director was paid up to the serviced period.

² Nicholas Falzon, company secretary, was appointed on 6 October 2010, is the partner of Lawler Partners Pty Ltd who provides accounting and company secretarial services to Cellmid Limited. The contract is based on normal commercial terms. A total of \$52,300 (2010 \$nil) was received by Lawler Partners Pty Limited in relation to this contract for the year.

³ Andrew Bursill, former company secretary, resigned on 5 October 2010. A total of \$22,428 (2010 \$65,549) in cash was received by Franks & Associates in relation to this contract for the year.

⁴ Robin Beaumont was appointed as director effective 12 October 2009 and has agreed to be paid 40% of his director's fees by way of options.

2010

Name	Short-term benefits			Post employment Benefits		Share-based payment	Total
	Cash salary and fees	Cash bonus	Non-monetary benefits	Super-annuation	Retirement benefits	Options	
	\$	\$	\$	\$	\$	\$	\$
<i>Non-executive directors</i>							
David King (Chairman) ⁵	65,000	-	-	5,750	-	-	70,750
Robin Beaumont ⁶	14,032	-	-	-	-	-	14,032
Koichiro Koike	45,087	-	-	-	-	57,000	102,087
Total non-executive directors	124,119	-	-	5,750	-	57,000	186,869
Executive directors and key Management							
Maria Halasz	350,000	-	-	31,500	-	198,100	390,583
Julia Hill ⁷	35,152	-	-	1,139	-	-	36,291
Andrew Bursill ⁸	-	-	-	-	-	-	-
Total executive directors and key Management	385,152	-	-	32,639	-	198,100	615,891
Total	509,271	-	-	38,389	-	255,100	802,760

⁵ An amount of \$43,333 is still due and payable to Dr King.

⁶ Robin Beaumont was appointed as director effective 12 October 2009 and has agreed to be paid 40% of his director's fees by way of options.

⁷ Julia Hill resigned on 4 August 2009.

⁸ Andrew Bursill, company secretary, is an associate of Franks & Associates Pty Limited who provided accounting and company secretarial services to Cellmid Limited until 5 October 2010. The contract was based on normal commercial terms. A total of \$65,549 (2009: \$11,206) in cash was received by Franks & Associates in relation to this contract for the year.

Directors' Report

Continued

The relative proportions of remuneration that are linked to performance and those that are fixed are as follows:

Name	Fixed remuneration		At risk STI		At risk LTI	
	2011	2010	2011	2010	2011	2010
Directors						-
David King	100%	100%	-	-	-	34%
Maria Halasz	100%	100%	-	-	-	-
Koichiro Koike	100%	100%	-	-	-	-
Robin Beumont	100%	100%	-	-	-	-
Other company and group executives						-
Nicholas Falzon	100%	N/A	-	-	-	-
Andrew Bursill	100%	100%	-	-	-	-

C. Service agreements (audited)

The CEO, Maria Halasz, is an employee of the group under an agreement signed on 21 September 2007. Under the terms of the present contract:

- Ms Halasz may resign from her position and thus terminate this contract by giving six months' written notice. On resignation any unvested options will be forfeited.
- The group may terminate the employment agreement by providing six months' written notice or providing payment in lieu of the notice period (based on the fixed component of Ms Halasz's remuneration).
- The group may terminate the contract at any time without notice if serious misconduct has occurred.. Where termination with cause occurs, the CEO is only entitled to that portion of remuneration which is fixed, and only up to the date of termination. On termination with cause, any unvested options will immediately be forfeited.
- Ms Halasz's employment agreement sets out certain performance incentives that are payable subject to achievement of specific milestones. Key milestones that trigger performance incentives are related to definitive agreement for the licensing or acquisition of new technology and the formation of a Clinical Advisory Board.

C. Share-based compensation

Options

2011

No options were granted to the directors for the year ended 30 June 2011

2010

	Options Granted in 2010	Value of options at grant date	Options Vested In 2010	Value of options expensed in 2010	Proportion of Remuneration
				\$	%
Maria Halasz	7,000,000	198,100	5,000,000	198,100	51%
Koichiro Koike	2,000,000	57,000	125,000	57,000	56%
	9,000,000	255,100	5,125,000	255,100	

The issuance of options to Directors, Executives and Key Management Personnel was approved by shareholders at the Annual General Meeting on 17 November 2009.

These options were granted for no consideration. The terms and conditions of the grant of option is convertible to one ordinary share of the Company.

Options granted carry no dividend or voting rights. Where exercisable, each option is convertible into one ordinary share of the Company.

The Executive options for Ms Halasz were granted at the date of approval being at the Annual General Meeting held on 17 November 2009. The options were issued in three separate tranches, having met all vesting conditions.

The assessed fair value at grant date of options granted is allocated over the period from grant date to vesting date. The amounts are included in the tables in Sections B and D above. Fair values at grant date are determined using a binomial option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date, the expected price volatility of the underlying share, the expected dividend yield and the risk-free rate for the term of the option.

The model inputs for options granted to Maria Halasz included:

- Options are granted for no consideration
- exercise price: \$0.045
- grant date: 17 November 2009
- expiry date: 17 November 2014
- share price at grant date: \$0.03
- share price volatility of the Company's shares: 175%
- expected dividend yield: nil%
- risk-free interest rate: 5.11%

The director options for Koichiro Koike were granted and vested in full at the date of approval being at the Annual General Meeting held on 17 November 2009.

Directors' Report

Continued

The assessed fair value at grant date of options granted is allocated over the period from grant date to vesting date. The amounts are included in the tables in Section B and D above. Fair values at grant date are determined using a binomial option pricing model that take into account the exercise price, the term of the option, the impact of dilution, the share price at grant date, the expected price volatility of the underlying share, the expected dividend yield and the risk-free rate for the term of the option.

The model inputs for the options granted to Koichiro Koike included:

- options are granted for no consideration
- exercise price: \$0.0375
- grant date: 17 November 2009
- expiry date: 17 November 2014
- share price at grant date: \$0.03
- expected price volatility of the Company's shares: 175%
- expected dividend yield: nil%
- risk-free interest rate: 5.14%

None of the director or executive options granted as share-based compensation were exercised during the period.

No options have been granted since the end of the financial year.

Loan to directors and executives

There were no loans to directors or executives during or since the end of the year.

Shares under option

Unissued ordinary shares of Cellmid Limited under option at the date of this report are as follows:

	Expiry Date	Issue Price	Number under option
			(\$)
Restricted options	8 January 2012	\$0.03	50,000
Unlisted options	15 June 2013	\$0.06	5,000,000
Unlisted options	8 January 2012	\$0.18	499,995
Unlisted options	8 January 2012	\$0.03	6,800,000
Unlisted options	1 June 2014	\$0.05	4,500,000
Unlisted options	1 July 2014	\$0.022	5,002,006
Unlisted options	17 November 2014	\$0.0283	7,000,000
Unlisted options	17 November 2014	\$0.0285	2,000,000
Unlisted options	19 February 2015	\$0.028	600,000
Unlisted options	15 December 2015	\$0.10	100,000
Total			31,552,001

Shares issued on the exercise of options

750,000 shares were issued during the year ended 30 June 2011 on the exercise of option (2010: nil).

No amounts are unpaid on any of the shares for the 2011 financial year (2010:\$nil).

Directors' and Officers' Liability Insurance

During the financial year, the group paid a premium to insure the directors and officers of the group.

The liabilities insured are legal costs that may be incurred in defending civil or criminal proceedings that may be brought against the officers in their capacity as officers of the group, and any other payments arising from liabilities incurred by the officers in connection with such proceedings. This does not include such liabilities that arise from conduct involving a wilful breach of duty by the officers or the improper use by the officers of their position or of information to gain advantage for them or someone else or to cause detriment to the company. It is not possible to apportion the premium between amounts relating to the insurance against legal costs and those relating to other liabilities.

Indemnifying Officers or Auditor

During or since the end of the financial year, the group has given an indemnity or entered into an agreement to indemnify, or paid or agreed to pay insurance premiums as follows:

- a right to access certain Board papers of the group during the period of their tenure and for a period of seven years after that tenure ends
- subject to the Corporation Act, an indemnity in respect of liability to persons other the group and its related bodies corporate that they may incur while acting in their capacity as an officer of the group or a related body corporate, except where that liability involves a lack of good faith and for defending certain legal proceedings, and
- the requirement that the group maintain appropriate directors' and officers' insurance for the officer.

No liability has arisen under these indemnities as at the date of the report.

There is no indemnity cover over the Auditor during the financial year.

Proceedings on behalf of the group

During the reporting period the group commenced proceeding against the Japanese Patent Office in the High Court of Japan in relation to the execution on registration of one of its patents.

Directors' Report

Continued

Non-audit services

The group may decide to employ the auditor on assignments additional to their statutory audit duties where the auditor's expertise and experience with the company and/or the group are important.

Details of the amounts paid or payable to the auditor, PKF for audit and non-audit services provided during the year are set out below.

	Consolidated group	
	2011	2010
	\$	\$
auditing or reviewing the financial statement		
<i>Pricewaterhouse Coopers</i>	-	44,010
<i>PKF</i>	26,000	15,000
taxation services	-	-
due diligence services	-	-
taxation services provided by related practice of auditor	-	-
	26,000	59,010

Rounding off of amounts

The Company is of the kind referred to in ASIC Class Order 98/0100, dated 10 July 1998, and in accordance with that Class Order amounts in the directors' report and the half-year financial report are rounded off to a dollar, unless otherwise indicated.

Auditor's Declaration

The lead auditor's independence declaration under s 307C of the Corporations Act 2001 is set out on page 23 for the year ended 30 June 2011.

This report is signed in accordance with a resolution of the Board of Directors made pursuant to s.306 (3) of the Corporations Act 2001.

On behalf of the directors



Dr David King
Chairman

Sydney
26th day of August 2011

Auditors' Independence Declaration

As lead auditor for the audit of Cellmid Limited for the year ended 30 June 2011, I declare that to the best of my knowledge and belief there have been:

- (a) no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- (b) no contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Cellmid Limited and the entity it controlled during the year.

**PKF**

Bruce Gordon
Partner
26 August 2011

Tel: 61 2 9251 4100 | Fax: 61 2 9240 9821 | www.pkf.com.au

PKF | ABN 83 236 985 726

Level 10, 1 Margaret Street | Sydney | New South Wales 2000 | Australia

The PKF East Coast Practice is a member of the PKF International Limited network of legally independent member firms. The PKF East Coast Practice is also a member of the PKF Australia Limited national network of legally independent firms each trading as PKF. PKF East Coast Practice has offices in NSW, Victoria and Brisbane. PKF East Coast Practice does not accept responsibility or liability for the actions or inactions on the part of any other individual member firm or firms.

Liability limited by a scheme approved under Professional Standards Legislation.



Corporate Governance Statement

Unless disclosed below, all the recommendations of the ASX Corporate Governance Council (including 2010 amendments) have been applied for the entire financial year ended 30 June 2011.

Board Composition

The skills, experience and expertise relevant to the position of each director who is in office at the date of the annual report and their term of office are detailed in the directors' report.

The names of independent directors of the company are:

- o David King
- o Robin Beaumont

When determining whether a non-executive director is independent, the director must not fail any of the following materiality thresholds:

- less than 10% of company shares are held by the director and any entity or individual directly or indirectly associated with the director;
- no sales are made to or purchases made from any entity or individual directly or indirectly associated with the director; and
- none of the directors' income or the income of an individual or entity directly or indirectly associated with the director is derived from a contract with any member of the economic entity other than income derived as a director of the entity.

Independent directors have the right to seek independent professional advice in the furtherance of their duties as directors at the company's expense. Written approval must be obtained from the Chair prior to incurring any expense on behalf of the company.

The names of the members of the nomination committee and their attendance at meetings of the committee are detailed in the directors' report.

Ethical Standards

The Board acknowledges and emphasises the importance of all directors and employees maintaining the highest standards of corporate governance practice and ethical conduct.

A code of conduct has been established requiring directors and employees to:

- act honestly and in good faith;
- exercise due care and diligence in fulfilling the functions of office;
- avoid conflicts and make full disclosure of any possible conflict of interest;
- comply with the law;
- encourage the reporting and investigating of unlawful and unethical behaviour; and
- comply with the share trading policy outlined in the code of conduct.

Directors are obliged to be independent in judgment and ensure all reasonable steps are taken to ensure due care is taken by the Board in making sound decisions.

Corporate Governance

Continued

Diversity Policy

Diversity includes, but is not limited to, gender, age, ethnicity and cultural background. The company is committed to diversity and recognises the benefits arising from employee and board diversity and the importance of benefiting from all available talent.

The Board believes that the company benefits from this diversity.

Trading Policy

The company's policy regarding directors and employees trading in its securities, is set by the Board. The policy restricts directors and employees from acting on material information until it has been released to the market and adequate time has been given for this to be reflected in the security's prices.

Audit Committee

The names and qualifications of those appointed to the audit committee and their attendance at meetings of the committee are included in the directors' report.

Performance Evaluation

An annual performance evaluation of the Board has not been made during the year.

Board Roles and Responsibilities

The Board is first and foremost accountable to provide value to its shareholders through delivery of timely and balanced disclosures.

The Board sought external guidance to assist the drafting of its "Board Governance Document" which has been made publicly available on the company's website. This document details the adopted practices and processes in relation to matters reserved for the Board's consideration and decision-making and specifies the level of authorisation provided to other key management personnel. The Board is ultimately responsible for ensuring its actions are in accordance with key corporate governance principles.

Shareholder Rights

Shareholders are entitled to vote on significant matters impacting on the business, which include the election and remuneration of directors, changes to the constitution and receipt of annual and interim financial statements. Shareholders are strongly encouraged to attend and participate in the Annual General Meetings of Cellmid Limited, to lodge questions to be responded by the Board and/or the CEO, and are able to appoint proxies.

Risk Management

The Board considers identification and management of key risks associated with the business as vital to maximise shareholder wealth. A yearly assessment of the business's risk profile is undertaken and reviewed by the Board, covering all aspects of the business from the operational level through to strategic level risks. The CEO has been delegated the task of implementing internal controls to identify and manage risks for which the Board provides oversight. The effectiveness of these controls is monitored and reviewed regularly. The worsening economic environment has emphasised the importance of managing and reassessing its key business risks.

Remuneration Policies

The company's remuneration committee comprises the following non-executive directors:

- o David King (Chair, independent);
- o Robin Beaumont (independent);

The remuneration policy, which sets the terms and conditions for the key management personnel, was developed by the remuneration committee after seeking professional advice from independent consultants and was approved by the Board. All executives receive a base salary, superannuation, fringe benefits, performance incentives and retirement benefits. The remuneration committee reviews executive packages annually by reference to company performance, executive performance, comparable information from industry sectors and other listed companies and independent advice. The performance of executives is measured against criteria agreed half yearly which is based on the forecast growth of the company's profits and shareholders' value. The policy is designed to attract the highest calibre executives and reward them for performance which results in long-term growth in shareholder value.

Executives are also entitled to participate in the employee share and option arrangements.

The amount of remuneration for all key management personnel of the company and the five highest paid executives, including all monetary and non-monetary components, are detailed in the directors' report under the heading key management personnel compensation. All remuneration paid to executives is valued at the cost to the company and expensed. Shares given to executives are valued as the difference between the market price of those shares and the amount paid by the executive. Options are valued using the Black-Scholes methodology.

The Board expects that the remuneration structure implemented will result in the company being able to attract and retain the best executives to run the consolidated group. It will also provide executives with the necessary incentives to work to grow long-term shareholder value.

The payment of bonuses, options and other incentive payments are reviewed by the remuneration committee annually as part of the review of executive remuneration and a recommendation is put to the Board for approval. All bonuses, options and incentives must be linked to predetermined performance criteria. The Board can exercise its discretion in relation to approving incentives, bonuses and options and can recommend changes to the committee's recommendations. Any changes must be justified by reference to measurable performance criteria.

Remuneration Committee

The names of the members of the remuneration committee and their attendance at meetings of the committee are detailed in the directors' report.

There are no schemes for retirement benefits other than statutory superannuation for non-executive directors.



Financial Report

Contents

Statement of Comprehensive Income	31
Statement of Financial Position	32
Statement of Changes in Equity	33
Statement of Cash Flows	34
Notes to the Financial Statements	35
Directors' declaration	64
Auditor's Report	65



Statements Of Comprehensive Income

For the year ended 30 June 2011

		Consolidated Group	
		2011	2010
	Note	\$	\$
Revenue	3	149,735	325,999
Other revenue	3	2,312	7,571
Cost of sales		(6,961)	-
Packaging		(35,590)	-
Consultancy fees		(229,760)	(177,973)
Communication expense		(50,570)	(12,709)
Depreciation and amortisation expense		(10,256)	(13,721)
Directors' remuneration		(154,208)	(124,117)
Professional fees		(76,362)	(35,111)
Employee benefits expense		(710,962)	(566,932)
Share-based compensation		(172,000)	(315,900)
Finance costs		(10,836)	(4,455)
Occupancy		(87,789)	(55,810)
Research and development costs		(925,137)	(306,466)
Travel		(107,503)	(106,259)
Loss on foreign exchange		(43,722)	(2,247)
Other expenses		(256,587)	(142,733)
Loss before income tax	4	(2,726,196)	(1,530,863)
Income tax benefit	5	456,559	190,915
Loss for the year	4	(2,269,637)	(1,339,948)
Net loss attributable to equity holders of Cellmid Limited		(2,269,637)	(1,339,948)
Other comprehensive income			
Net gain on remeasurement of financial assets available for sale	20a	6,227	3,893
Total comprehensive loss for the year		(2,263,410)	(1,336,055)
Earnings per share for loss attributable to the ordinary equity holders of the Company		Cents	Cents
Basic earnings per share (cents)	8	(0.65)	(0.48)
Diluted earnings per share (cents)	8	(0.65)	(0.48)

The above statement of comprehensive income should be read in conjunction with the accompanying notes

Statements Of Financial Position

As at 30 June 2011

		Consolidated Group	
		2011	2010
	Note	\$	\$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	9	1,592,508	2,093,185
Trade and other receivables	10	27,603	34,667
Inventories	11	1,097,182	1,000,000
Other assets	15	31,255	22,274
TOTAL CURRENT ASSETS		2,748,548	3,150,126
NON-CURRENT ASSETS			
Other financial assets	12	60,120	53,893
Plant and equipment	13	11,764	14,232
Intangible assets	14	1,440	-
TOTAL NON-CURRENT ASSETS		73,324	68,125
TOTAL ASSETS		2,821,872	3,218,251
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	16	133,705	312,760
Borrowings	17	556,835	-
Provisions	18	93,364	56,552
TOTAL CURRENT LIABILITIES		783,904	369,312
NON-CURRENT LIABILITIES		-	-
TOTAL LIABILITIES		783,904	369,312
NET ASSETS		2,037,968	2,848,939
EQUITY			
Contributed equity	19	18,838,712	17,386,273
Reserves	20	1,670,351	1,664,124
Accumulated losses	20	(18,471,095)	(16,201,458)
TOTAL EQUITY		2,037,968	2,848,939

This statement of financial position should be read in conjunction with the accompanying notes.

Statements Of Changes In Equity

For the year ended 30 June 2011

Consolidated Group		Share Capital				
	Note	Issued Capital	Share Based Payments Reserve	Available for Sale Reserve	Accumulat- ed Losses	Total
		\$	\$	\$	\$	\$
Balance at 1 July 2009		14,255,828	1,344,331	-	(14,861,510)	738,649
Total comprehensive income for the year		-	-	3,893	(1,339,948)	(1,336,055)
Transactions with equity holders:						
Contributions of equity		3,380,221	-	-	-	3,380,221
Capital raising costs		(249,776)	-	-	-	(249,776)
Movement in share based payment reserve		-	315,900	-	-	315,900
Total		3,130,445	315,900	3,893	(1,339,948)	2,110,290
Balance at 30 June 2010	19,20	17,386,273	1,660,231	3,893	(16,201,458)	2,848,939
Balance at 1 July 2010		17,386,273	1,660,231	3,893	(16,201,458)	2,848,939
Total comprehensive income for the year		-	-	6,227	(2,269,637)	(2,263,410)
Transactions with equity holders:						
Contributions of equity		1,280,439	-	-	-	1,280,439
Share based compensa- tion		172,000	-	-	-	172,000
Movement in share based payment reserve		-	-	-	-	-
Total		1,452,439	-	6,227	(2,269,637)	(810,971)
Balance at 30 June 2011	19,20	18,838,712	1,660,231	10,120	(18,471,095)	2,037,968

This statement of changes in equity should be read in conjunction with the accompanying notes.

Cash Flow Statements

For the year ended 30 June 2011

	Note	Consolidated Group	
		2011	2010
		\$	\$
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		31,169	-
Payments to suppliers and employees		(2,008,420)	(1,354,399)
Research and development expenses		(925,137)	(283,271)
Revenue and other income		19,555	219,739
Interest received		50,813	64,032
R & D grant income		456,559	190,915
Other grant income		57,574	-
Finance costs		(10,836)	(4,455)
Net cash used in operating activities	21	(2,328,723)	(1,167,439)
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of trademarks		(1,440)	-
Purchase of plant and equipment		(7,788)	(6,961)
Net cash used in investing activities		(9,228)	(6,961)
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from issue of shares		1,280,439	3,130,445
Proceeds from borrowings		556,835	-
Repayment of borrowings		-	(26,021)
Net cash provided by financing activities		1,837,274	3,104,424
Net increase (decrease) in cash held		(500,677)	1,930,024
Cash and cash equivalents at beginning of financial year	9	2,093,185	163,161
Cash and cash equivalents at end of financial year	9	1,592,508	2,093,185

This statement of cash flows should be read in conjunction with the accompanying notes.

These consolidated financial statements and notes represent those of Cellmid Limited and Controlled Entity (the "consolidated group" or "group").

The separate financial statements of the parent entity, Cellmid Limited, have been presented in note 2 within this financial report.

The financial statements were authorised for issue on 26th August 2011 by the directors of the company.

Notes to the Financial Statements

Contents

1	Summary of Significant Accounting Policies	36
2	Parent Information	43
3	Revenue and Other Revenue	44
4	Profit/(Loss) for the year	44
5	Income Tax Expense	45
6	Interests of Key Management Personnel (KMP)	47
7	Auditors' Remuneration	50
8	Earnings per Share	50
9	Cash and Cash Equivalents	51
10	Trade and Other Receivables	51
11	Inventories	52
12	Other Financial Assets	52
13	Plant and Equipment	13
14	Intangible Assets	54
15	Other Assets	54
16	Trade and Other Payables	54
17	Borrowings	55
18	Provisions	55
19	Contributed Equity	56
20	Reserves and Accumulated Losses	59
21	Cash Flow Information	60
22	Critical Accounting estimates and Judgements	60
23	Events after the Reporting Period	61
24	Related Party Transactions	61
25	Financial Risk Management	62
26	Controlled Entity	63

Notes to the Financial Statements

Continued

NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Statement of compliance

The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards, Australian Accounting Interpretations, other authoritative pronouncements of the Australian Accounting Standards Board (AASB) and the Corporations Act 2001.

The financial statements comprise the consolidated financial statements of the group.

The financial statements were authorised for issue by the directors on 26 August 2011.

Basis of Preparation

The financial statements have been prepared on an accruals basis and are based on historical costs, except for certain non-current assets and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair values of the consideration given in exchange for assets. All amounts are presented in Australian dollars, unless otherwise noted.

The preparation of financial statements in conformity with AIFRS requires the use of certain accounting estimates. It also requires management to exercise its judgement in the process of applying the group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in Note 22.

a. Principles of Consolidation

The consolidated financial statements incorporate the assets, liabilities and results of entities controlled by Celmid Limited at the end of the reporting period. A controlled entity is any entity over which Celmid Limited has the ability and right to govern the financial and operating policies so as to obtain benefits from the entity's activities.

Income and expenses of subsidiaries acquired or disposed of during the year are included in the consolidated statement of comprehensive income from the effective date of acquisition and up to the effective date of disposal, as appropriate. Total comprehensive income of subsidiaries is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interest having a deficit balance.

Where necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by other members of the group.

All intra-group transactions, balances, income and expenses are eliminated in full on consolidation.

b. Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision makers, who are responsible for allocating resources and assessing performance of the operating segments, are the Board of directors.

c. Revenue and Other Income Recognition

Revenue is measured at the fair value of the consideration received or receivable after taking into account any trade discounts and volume rebates allowed.

Revenue from the sale of goods is recognised at the point of delivery as this corresponds to the transfer of significant risks and rewards of ownership of the goods and the cessation of all involvement in those goods.

Interest revenue is recognised using the effective interest rate method.

Royalties determined on a time basis are recognised on a straight-line basis over the period of the agreement.

Government grants are recognised in profit and loss on a systematic basis over the periods in which the group recognises as expenses the related costs for which the grants are intended to compensate.

d. Income Tax

The income tax expense (revenue) for the period is the tax payable on the current period's taxable income based on the national income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses.

Deferred tax assets and liabilities are calculated at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled and their measurement also reflects the manner in which management expects to recover or settle the carrying amount of the related asset or liability.

Deferred tax assets relating to temporary differences and unused tax losses are recognised only to the extent that it is probable that future taxable profit will be available against which the benefits of the deferred tax asset can be utilised.

Current tax assets and liabilities are offset where a legally enforceable right of set-off exists and it is intended that net settlement or simultaneous realisation and settlement of the respective asset and liability will occur. Deferred tax assets and liabilities are offset where: (a) a legally enforceable right of set-off exists; and (b) the deferred tax assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities where it is intended that net settlement or simultaneous realisation and settlement of the respective asset and liability will occur in future periods in which significant amounts of deferred tax assets or liabilities are expected to be recovered or settled.

e. Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits available on demand with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are reported within short-term borrowings in current liabilities in the statement of financial position.

f. Receivable

Receivables are recognised initially at fair value and subsequently measured at amortised cost, less provision for doubtful debts.

Collectability of receivables is reviewed on an ongoing basis. Debts which are known to be uncollectible are written off. A provision for doubtful receivables is established when there is objective evidence that the group will not be able to collect all amounts due according to the original terms of receivables. The amount of the provision is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. Cash flows relating to short term receivables are not discounted if the effect of discounting is immaterial. The amount of the provision is recognised in the statement of comprehensive income.

g. Inventories

Inventories are measured at the lower of cost and net realisable value. The cost of manufactured products includes direct materials, direct labour and an appropriate portion of variable and fixed overheads. Overheads are applied on the basis of normal operating capacity. Costs are assigned on the basis of weighted average costs. Costs of purchased inventory are determined after deducting rebates and discounts. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated cost necessary to make the sale.

h. Fixtures and Equipment

Fixtures and equipment are measured on the cost basis and therefore carried at cost less accumulated depreciation and any accumulated impairment.

The cost of fixed assets constructed within the consolidated group includes the cost of materials, direct labour, borrowing costs and an appropriate proportion of fixed and variable overheads.

Notes to the Financial Statements

Continued

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. All other repairs and maintenance are charged to the statement of comprehensive income during the financial period in which they are incurred.

Depreciation

The depreciable amount of all fixed assets is depreciated on a straight-line basis over the asset's useful life to the consolidated group commencing from the time the asset is held ready for use. Leasehold improvements are depreciated over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements.

The depreciation rates used for each class of depreciable assets are:

Class of Fixed Asset	Depreciation Rate
Furniture and fittings	20%
Office equipment	6.7–33.33%

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains and losses are included in the statement of comprehensive income. When revalued assets are sold, amounts included in the revaluation surplus relating to that asset are transferred to retained earnings.

i. Investments and other financial assets

The group classified its investments in the following categories: loans and receivables and available for sale financial assets.

The classification depends on the nature and purpose of the investment and is determined at the time of initial recognition.

(i) Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are subsequently measured at amortised cost.

Loans and receivables are included in current assets, where they are expected to mature within 12 months after the end of the reporting period.

Loan and receivables are measured at amortised cost using the effective interest method, less any impairment. Interest income is recognised by applying the effective interest rate, except for short-term receivables when the recognition of interest would be immaterial.

(ii) Available-for-sale financial assets

Listed shares and listed redeemable notes held by the group that are traded in an active market are classified as available-for-sale financial assets and are stated at fair value.

Gains and losses arising from changes in fair value are recognised in other comprehensive income and accumulated in the investments revaluation reserve.

Where the investment is disposed of or is determined to be impaired, the cumulative gain or loss previously accumulated in the investment revaluation reserve is reclassified to profit and loss.

The fair value of available-for-sale assets denominated in a foreign currency is determined in that foreign currency and translated at the spot rate at the end of the reporting period. The foreign exchange gains and losses that are recognised in profit and loss are determined based on the amortised cost of the monetary asset. Other foreign gains and losses are recognised in other comprehensive income.

j. Intangibles other than Goodwill

Patents and trademarks

Patents and trademarks are recognised at cost of acquisition. Patents and trademarks have a finite life and are carried at cost less any accumulated amortisation and any impairment losses. The group has not yet determined the useful life of the intangible asset due to the uncertainties of the future benefit derived from the intangible asset. There is no amortisation charge to the intangible assets in the 2011 financial Year.

Research and development

Expenditure on research activities is recognised as an expense in the period in which it is incurred.

Expenditure on development projects (relating to the design and testing of new or improved products) are capitalised as intangible assets when it is probable that the project will be a success considering its commercial and technical feasibility and its costs can be measured reliably. The expenditure capitalised comprises all directly attributable costs, including costs of materials, services, direct labour and an appropriate proportion of overheads. Development expenditures that do not meet these criteria are recognised as an expense as incurred. Development costs previously recognised as an expense are not recognised as an asset in a subsequent period.

k. Impairment of Assets

At the end of each reporting period, the group assesses whether there is any indication that an asset may be impaired. The assessment will include the consideration of external and internal sources of information including dividends received from subsidiaries, associates or jointly controlled entities deemed to be out of pre-acquisition profits. If such an indication exists, an impairment test is carried out on the asset by comparing the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use, to the asset's carrying amount. Any excess of the asset's carrying amount over its recoverable amount is recognised immediately in profit or loss, unless the asset is carried at a revalued amount in accordance with another Standard (e.g. in accordance with the revaluation model in AASB 116). Any impairment loss of a revalued asset is treated as a revaluation decrease in accordance with that other Standard.

Where it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Impairment testing is performed annually for goodwill and intangible assets with indefinite lives.

l. Trade and other payables

These amounts represent liabilities for goods and services provided to the group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition.

m. Borrowings

Borrowings are initially recognised at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortised cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in the statement of comprehensive income over the period of the borrowings using the effective interest method.

Borrowings are classified as current liabilities unless the group has an unconditional right to defer settlement of the liability for at least 12 months after the reporting date.

Notes to the Financial Statements

Continued

n. Financial Instruments

The convertible notes issued by the company are treated as a financial liability, without an equity component. They are treated in this manner because; they have multiple settlement alternatives not all of which involve the exchange of equity, the number of shares to be issued is unknown at the time of issue and the conversion is at the option of the note holder not the company.

o. Provisions

Provisions are recognised when the group has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured.

Provisions are measured using the best estimate of the amounts required to settle the obligation at the end of the reporting period.

p. Employee Benefits

Provision is made for the group's liability for employee benefits arising from services rendered by employees to the end of the reporting period. Employee benefits that are expected to be settled within the income year have been measured at the amounts expected to be paid when the liability is settled. Employee benefits payable later than 12 months of the reporting date have been measured at the present value of the estimated future cash outflows to be made for those benefits. In determining the liability, consideration is given to employee wages increases and the probability that the employee may satisfy vesting requirements.

Wages and salaries, annual leave and sick leave

Liability for wages and salaries, including non monetary benefits, annual leave and accumulating sick leave expected to be settled within 12 months of the reporting date are recognised in other payables in respect of employees' services up to the reporting date and are measured at the amounts expected to be paid when the liabilities are settled.

Long service leave

Liability for long service leave is recognised in the provision for employee benefits and measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and period of service

Retirement benefit obligations

Contributions to the defined contribution fund are recognised as an expense as they become payable. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in the future payment is available. Contributions are paid into the fund nominated by the employee.

Share-based payments

The fair value of options granted is recognised as a benefit expense with a corresponding increase in equity. The fair value is measured at grant date and recognised over the period during which the directors and executives become unconditionally entitled to the options.

The fair value at grant date is determined using binomial option pricing model that takes into account the exercise price, the term of option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option.

The fair value of the options granted is adjusted to reflect market vesting conditions, but excludes the impact of any non market vesting conditions. Non market vesting conditions are included in assumptions about the number of options that are expected to become exercisable. The benefit expense recognised each period takes into account the most recent estimate.

Upon the exercise of options, the balance of the share based payments reserve relating to those options is transferred to share capital and the proceeds received, net of any directly attributable transaction costs, are credited to share capital.

q. Equity-settled compensation

The group operates an employee share ownership plan. Share-based payments to employees are measured at the fair value of the instruments issued and amortised over the vesting periods. Share-based payments to non-employees are measured at the fair value of goods or services received or the fair value of the equity instruments issued, if it is determined the fair value of the goods or services cannot be reliably measured, and are recorded at the date the goods or services are received. The corresponding amount is recorded in the option reserve. The fair value of options is determined using the binominal pricing model. The number of shares and options expected to vest is reviewed and adjusted at the end of each reporting period such that the amount recognised for services received as consideration for the equity instruments granted is based on the number of equity instruments that eventually vest.

Upon the exercise of options, the balance of the share based payments reserve relating to those options is transferred to share capital and the proceeds received, net of any directly attributable transaction costs, are credited to share capital.

r. Functional and presentation currency

The functional currency of each of the group's entities is measured using the currency of the primary economic environment in which that entity operates. The consolidated financial statements are presented in Australian dollars which is the parent entity's functional and presentation currency.

s. Transactions and balances

Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the year-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined.

Exchange differences arising on the translation of monetary items are recognised in profit or loss, except where deferred in equity as a qualifying cash flow or net investment hedge.

Exchange differences arising on the translation of non-monetary items are recognised directly in other comprehensive income to the extent that the underlying gain or loss is recognised in other comprehensive income; otherwise the exchange difference is recognised in profit or loss.

t. Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO).

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to, the ATO are presented as operating cash flows included in receipts from customers or payments to suppliers.

u. Government Grants

Government grants are recognised at fair value where there is reasonable assurance that the grant will be received and all grant conditions will be met. Grants relating to expense items are recognised as income over the periods necessary to match the grant to the costs they are compensating. Grants relating to assets are credited to deferred income at fair value and are credited to income over the expected useful life of the asset on a straight-line basis.

Notes to the Financial Statements

Continued

v. Comparative Figures

When required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year.

Where the group has retrospectively applied an accounting policy, made a retrospective restatement of items in the financial statements or reclassified items in its financial statements, an additional statement of financial position as at the beginning of the earliest comparative period will be disclosed.

w. Rounding of Amounts

The parent entity has applied the relief available to it under ASIC Class Order 98/100 and accordingly, amounts in the financial statements and directors' report have been rounded off to the nearest \$1.

x. New Accounting Standards for Application in Future Periods

The AASB has issued new and amended Accounting Standards and Interpretations that have mandatory application dates for future reporting periods and which the group has decided not to early adopt. A discussion of those future requirements and their impact on the group is as follows:

- ***AASB 9: Financial Instruments (December 2010) (applicable for annual reporting periods commencing on or after 1 January 2013).***

This Standard is applicable retrospectively and includes revised requirements for the classification and measurement of financial instruments, as well as recognition and derecognition requirements for financial instruments. The group has not yet determined any potential impact on the financial statements.

However, initial indications are that it may affect the group's accounting for its available-for-sale financial assets, since AASB 9 only permits the recognition of fair value gains and losses in other comprehensive income if they relate to equity investments that are not held for trading. Fair value gains and losses on available-for-sale debt investments, for example, will therefore have to be recognised directly in profit or loss. In the current reporting period, the group recognised \$6,227 of such gains in other comprehensive income. The group has not yet decided when to adopt AASB 9.

- ***AASB 124: Related Party Disclosures (applicable for annual reporting periods commencing on or after 1 January 2011).***

This Standard removes the requirement for government-related entities to disclose details of all transactions with the government and other government-related entities and clarifies the definition of a "related party" to remove inconsistencies and simplify the structure of the Standard. No changes are expected to materially affect the group.

NOTE 2: PARENT INFORMATION

	2011	2010
	\$	\$
The following information has been extracted from the books and records of the parent and has been prepared in accordance with Accounting Standards.		
STATEMENT OF FINANCIAL POSITION		
ASSETS		
Current assets	2,912,584	3,149,607
TOTAL ASSETS	2,983,845	3,217,733
LIABILITIES		
Current liabilities	(776,202)	(369,312)
TOTAL LIABILITIES	(776,202)	(369,312)
EQUITY		
Issued capital	18,838,712	17,368,273
Accumulated losses	(18,301,420)	(16,201,976)
Share Based Payment Reserve	1,660,231	1,660,231
Available for sale asset reserve	10,120	3,893
TOTAL EQUITY	2,207,643	2,848,421
STATEMENT OF COMPREHENSIVE INCOME		
Loss of the parent entity	(2,093,792)	(1,335,944)
Total comprehensive loss	(2,093,792)	(1,335,944)

Notes to the Financial Statements

Continued

NOTE 3: REVENUE AND OTHER REVENUE

	Consolidated Group	
	2011	2010
	\$	\$
Revenue from continuing operations		
Sales revenue:		
– sale of goods	29,106	-
– interest received	50,813	63,831
– government grants received	57,574	-
– rental revenue	12,000	-
– royalties	242	262,168
	149,735	325,999
Other revenue:		
– other revenue	2,312	7,571
	2,312	7,571
Total revenue	152,047	333,570

NOTE 4: PROFIT/(LOSS) FOR THE YEAR

	Consolidated Group	
	2011	2010
	\$	\$
Loss before income tax from continuing operations includes the following specific expenses:	(2,269,637)	(1,339,948)
Cost of sales	(6,961)	-
Finance costs	(10,836)	(4,455)
Employee benefits expense	(710,962)	(566,932)
Foreign currency translation losses	(43,722)	(2,247)
Rental expense on operating leases:		
– minimum lease payments	(87,789)	(55,810)
Depreciation and amortisation		
– Plant and equipment	(10,256)	(13,721)
Research and development costs	(925,137)	(306,466)

NOTE 5: INCOME TAX EXPENSE

	Note	Consolidated Group	
		2011	2010
		\$	\$
a. The components of tax expense comprise:			
Current tax		-	-
Deferred tax		-	-
Income tax benefit		456,559	190,915
		456,559	190,915
b. Numerical reconciliation of income tax expenses to:			
– Loss before income tax expenses		(2,726,196)	(1,530,863)
Prima facie tax payable on profit from ordinary activities before income tax at 30% (2010: 30%)		(817,859)	(459,259)
<i>Add:</i>			
Tax effect of:			
– Research and development expenditure		401,259	197,161
– Share based payment		51,600	94,770
– Sundry items		10,184	1,098
		463,043	293,029
Adjusted income tax		(354,816)	(166,230)
Tax losses not brought to account		(354,816)	(166,230)
Research and development tax offset		456,559	190,915
Income tax benefit		456,559	190,915

A \$456,559 (2010 \$190,915) research and development tax offset was received for a claim in accordance with the Commonwealth Government's Research and Development Tax Concession initiatives where the consolidated group's expenditure on research and development is below \$1million and revenue is less than \$5 million.

Notes to the Financial Statements

Continued

NOTE 5: INCOME TAX EXPENSE (CONTINUED)

	Note	Consolidated Group	
		2011	2010
		\$	\$
c. Tax losses			
Unused tax losses for which no deferred tax asset has been recognised		1,182,721	3,746,416
Temporary difference deferred tax assets not recognised		167,864	(95,585)
Potential future tax benefit at notional tax rate 30%		405,175	1,095,249

All unused tax losses were incurred by Australian entities.

This income tax benefit arose from losses will only be obtained if:

- The group derives future assessable income of a nature and of an amount sufficient to enable to benefit from the deductions for the losses to be realised;
- The group continues to comply with the conditions for deductibility imposed by tax legislation; and
- No changes in tax legislation adversely affect the consolidated entity in realising the benefit from the deductions for the losses.

d. Deferred tax assets and liabilities

The balance comprises temporary differences attributable to:

Deferred tax asset amounts recognised in profit or loss arose from:

Accrued expenses claimable in future periods	167,864	158,460
--	----------------	---------

Set-off of deferred tax liability recognised in profit or loss arose from

Amortisation	-	(254,045)
--------------	---	-----------

Net temporary difference	167,864	(95,585)
--------------------------	----------------	----------

Net deferred tax assets (liabilities) not recognised	-	-
--	---	---

e. Tax consolidation legislation

Cellmid Limited and its wholly owned Australian entity have tax consolidated during the financial year.

NOTE 6: INTERESTS OF KEY MANAGEMENT PERSONNEL (KMP)

a. Directors

The following persons were directors of Cellmid Limited during the financial year:

David King (Chairman)

- appointed from 18 January 2008 to current

Ms Maria Halasz (Chief Executive Officer)

- appointed from 16 April 2007 to current

Mr Koichiro Koike (Non executive)

- appointed from 10 September 2008 and resigned on 10 December 2010

Mr Robin Beaumont (Non executive)

- appointed from 12 October 2009 to current

b. Directors and key management personnel compensation

Refer to the remuneration report contained in the directors' report for details of the remuneration paid or payable to each member of the group's key management personnel for the year ended 30 June 2011.

The totals of remuneration paid to KMP of the company and the group during the year are as follows:

	2011	2010
	\$	\$
Short-term employee benefits	507,734	509,271
Post-employment benefits	38,100	38,389
Share-based payments	-	255,100
	<u>545,834</u>	<u>802,760</u>

c. Equity instrument disclosures relating to key management personnel

Options provided as remuneration and shares issued on exercise of such options

Details of options provided as remuneration, together with terms and conditions of the options, can be found in note 19.

Notes to the Financial Statements

Continued

NOTE 6: INTERESTS OF KEY MANAGEMENT PERSONNEL (KMP)

(i) KMP Options Holdings

The numbers of options over ordinary shares in the Company held during the financial year by each director of Cellmid Limited and other key management personnel of the group, including their personally related parties, are set out in the table below.

30 June 2011	Balance at Beginning of the Year	Granted as remuneration during the Year	Exercised during the Year	Other Changes during the Year	Balance at end of Year	Vested and Exercisable at the end of the Year
<i>Directors of Cellmid Limited</i>						
M Halasz	12,000,000	-	-	-	-	12,000,000
D King	-	-	-	-	-	-
K Koike	2,000,000	-	-	-	-	2,000,000
R Beaumont	-	-	-	-	-	-
<i>Other key management personnel</i>						
N Falzon	-	-	-	-	-	-
A Bursill	-	-	-	-	-	-

30 June 2010	Balance at Beginning of the Year	Granted as remuneration during the Year	Exercised during the Year	Other Changes during the Year	Balance at end of Year	Vested and Exercisable at the end of the Year
<i>Directors of Cellmid Limited</i>						
M Halasz	5,000,000	7,000,000	-	-	-	12,000,000
D King	-	-	-	-	-	-
K Koike	-	2,000,000	-	-	-	2,000,000
R Beaumont	-	-	-	-	-	-
<i>Other key management personnel</i>						
A Bursill	-	-	-	-	-	-

NOTE 6: INTERESTS OF KEY MANAGEMENT PERSONNEL (KMP)

(ii) KMP Shareholdings

The numbers of shares in the Company held during the financial year by each director and key management personnel of Cellmid Limited, including their personally related parties, are set out below. There were no shares granted during the reporting period as compensation.

30 June 2011	Balance at Beginning of the Year	Received during the Year on the exercise of options	Other Changes during the Year	Balance at the end of the Year
<i>Directors of Cellmid Limited</i>				
M Halasz	1,099,250	-	318,750	1,418,000
D King	10,010,000	-	3,466,669	13,476,669
K Koike	-	-	-	-
R Beaumont	400,000	-	300,000	700,000
<i>Other key management personnel</i>				
N Falzon	-	-	-	-
A Bursill	-	-	-	-

Maria Halasz owns 1,418,000 shares indirectly.

David King owns 13,476,669 shares indirectly.

Robin Beaumont owns 700,000 shares indirectly.

30 June 2010	Balance at Beginning of the Year	Received during the Year on the exercise of options	Other Changes during the Year	Balance at the end of the Year
<i>Directors of Cellmid Limited</i>				
M Halasz	439,250	-	660,000	1,099,250
D King	9,555,000	-	455,000	10,010,000
K Koike	-	-	-	-
R Beaumont	-	-	400,000	400,000
<i>Other key management personnel</i>				
A Bursill	-	-	-	-

(iii) Other KMP Transactions

There have been no other transactions involving equity instruments other than those described in the tables above. The Chief Executive Officer is employed under an employment service contract.

Notes to the Financial Statements

Continued

NOTE 7: AUDITORS' REMUNERATION

During the year the following fees were paid or payable for services provided by the auditor of the parent entity, its related practices and a non-related audit firm:

	Consolidated Group	
	2011	2010
	\$	\$
- auditing or reviewing the financial statement		
<i>Pricewaterhouse Coopers</i>	-	44,010
<i>PKF</i>	26,000	15,000
- taxation services	-	-
- due diligence services	-	-
- taxation services provided by related practice of auditor	-	-

NOTE 8: EARNINGS PER SHARE

	Consolidated Group	
	2011	2010
	\$	\$
a. Basic and diluted earnings per share:		
Earnings used in the calculation of dilutive EPS	(0.65)	(0.48)
b. Loss used in calculating basic and diluted earnings per share:		
Loss	(2,269,637)	(1,339,948)
c. Weighted average number of shares used as the denominator		
	No.	No.
Weighted average number of ordinary shares used in calculating dilutive EPS	350,019,302	277,273,648

d. Information concerning the classification of securities.

Options

Options granted to executives and directors are considered to be potential ordinary shares and have been included in the determination of diluted earnings per share to the extent to which they are dilutive. In the year ended 30 June 2011, these options were in fact anti-dilutive, and consequently diluted EPS is the same as basis EPS. The options have not been included in the determination of basic earnings per share. Details relating to the options are set out in Note 19.

NOTE 9: CASH AND CASH EQUIVALENTS

	Consolidated Group	
	2011	2010
	\$	\$
Cash at bank and in hand	1,592,508	2,093,185
	<u>1,592,508</u>	<u>2,093,185</u>

The effective interest rate on short-term bank deposits was 4-4.5% (2010: 4-4.5%); these deposits were all on call.

Reconciliation of cash

Cash at the end of the financial year as shown in the statement of cash flows is reconciled to items in the statement of financial position as follows:

Cash and cash equivalents	1,592,508	2,093,185
	<u>1,592,508</u>	<u>2,093,185</u>

NOTE 10: TRADE AND OTHER RECEIVABLES

	Consolidated Group	
	2011	2010
	\$	\$
Trade receivables	3,112	-
Other receivables	24,491	34,667
Total current trade and other receivables	<u>27,603</u>	<u>34,667</u>

Effective interest rates and credit risk

The group has no significant concentration of credit risk with respect to any single counterparty or group of counterparties other than those receivables specifically provided for and mentioned within Note 10. The class of assets described as "trade and other receivables" is considered to be the main source of credit risk related to the group.

There is no interest rate risk for the balances of Trade and Other receivables.

There is no material credit risk associated with Other receivables.

Notes to the Financial Statements

Continued

NOTE 11: INVENTORIES

	Consolidated Group	
	2011	2010
	\$	\$
Inventory at lower of cost and net realisable value	1,097,182	1,000,000
Total inventories	1,097,182	1,000,000

NOTE 12: OTHER FINANCIAL ASSETS

	Consolidated Group	
	2011	2010
	\$	\$
Available-for-sale financial assets	60,120	53,893
Total non-current financial assets	60,120	53,893

Available-for-sale financial assets

Listed investments, at fair value:

- shares in listed corporations

Total available-for-sale financial assets

60,120	53,893
60,120	53,893

NOTE 13: PLANT AND EQUIPMENT

	Consolidated Group	
	2011	2010
	\$	\$
PLANT AND EQUIPMENT		
Plant and equipment:		
At cost	97,828	90,040
Accumulated depreciation	(86,064)	(75,808)
Total plant and equipment	11,764	14,232

Movements in Carrying Amounts

Movements in the carrying amounts for each class of plant and equipment between the beginning and the end of the current financial year:

	Plant and Equipment	Total
	\$	\$
Consolidated Group		
Balance at 1 July 2009	20,991	20,991
Additions	6,961	6,961
Disposals	-	-
Depreciation expense	(13,720)	(13,720)
Balance at 30 June 2010	14,232	14,232
Additions	7,788	7,788
Disposals	-	-
Depreciation expense	(10,256)	(10,256)
Balance at 30 June 2011	11,764	11,764

Notes to the Financial Statements

Continued

NOTE 14: INTANGIBLE ASSETS

	Trademarks & Licences
	\$
Consolidated Group:	
Year ended 30 June 2010	
Balance at 1 July 2009	-
Additions	-
Disposals	-
Amortisation charge	-
Impairment losses	-
	-
Year ended 30 June 2011	
Balance at 1 July 2010	-
Additions	1,440
Internal development	-
Disposals	-
Amortisation charge	-
Impairment losses	-
Closing value at 30 June 2011	1,440

Intangible assets, other than goodwill, have finite useful lives. The group has not yet determined the useful life of the intangible asset.

There is no amortisation charge to the intangible assets in the 2011 financial year.

NOTE 15: OTHER ASSETS

	Consolidated Group	
	2011	2010
	\$	\$
Prepayments	31,255	22,274
Total other assets	31,255	22,274

NOTE 16: TRADE AND OTHER PAYABLES

	Consolidated Group	
	2011	2010
	\$	\$
Unsecured liabilities:		
Trade payables	1,471	62,137
Sundry payables and accrued expenses	132,234	250,623
	133,705	312,760

NOTE 17: BORROWINGS

	Consolidated Group	
	2011	2010
	\$	\$
Convertible notes	556,835	-
	<u>556,835</u>	<u>-</u>

Convertible notes

Each loan has a repayment term of 5 years. The conversion price is the lesser of the price calculated as a 20% discount to the three lowest daily volume weighted average sales prices of the Company's shares during the 21 days before conversion or AU\$0.09 (for notes issued in the first 12 months) and AU\$0.15 (for notes issued afterwards).

Conversion will generally be at the note holders' option except in the event that on the conversion date the Company's shares trade below a floor price of AU\$0.025. In this instance Cellmid may elect to repay the face value of the Note plus a 5% premium.

Interest expenses on convertible notes is calculated by applying the effective interest rate of 4.75% (2010 Nil%) to the liability component.

NOTE 18: PROVISIONS

	Employee Benefits Annual Leave \$
Consolidated Group	
Opening balance at 1 July 2010	56,552
Additional provisions	36,812
Balance at 30 June 2011	<u>93,364</u>

Analysis of total provisions

	Consolidated Group	
	2011	2010
	\$	\$
Current	93,364	56,552
	<u>93,364</u>	<u>56,552</u>

Provision for Employee Benefits

A provision has been recognised for employee entitlements relating to annual leave. There is no long service leave being recognised in the 2011 financial year.

Notes to the Financial Statements

Continued

NOTE 19: CONTRIBUTED EQUITY

		Consolidated Group			
	Note	2011 No.	2010 No.	2011 \$	2010 \$
a. Share Capital					
At at the beginning of the year		325,781,294	187,571,266	17,328,284	14,197,839
Shares issued during the year		66,852,835	138,210,028	1,452,439	3,130,445
At the end of the year	19.c	392,634,129	325,781,294	18,780,723	17,328,284
b. Options					
Balance the beginning of the year		32,702,001	18,099,995	57,989	57,989
Listed		-	-	-	-
Managing Director (M Halasz)		-	7,000,000	-	-
Other		(650,000)	5,602,006	-	-
Directors		-	2,000,000	-	-
Executives		-	-	-	-
At the end of the year	19.d	32,052,001	32,702,001	57,989	57,989
Total contributed equity				18,838,712	17,386,273

NOTE 19: CONTRIBUTED EQUITY (CONTINUED)

c. Movement in ordinary share capital

Date	Details	Consolidated Group		\$
		Number of shares	Issued price	
	Opening balance 1 July 2009	187,571,266		14,197,839
07 Jul 2009	Exercise of converting note options	25,010,028	0.022	550,221
26 Nov 2009	Shares issued	113,200,000	0.025	2,830,000
	Less transaction costs arising on share issue			(249,776)
	Closing balance 30 June 2010	325,781,294		17,328,284
	Opening balance 1 July 2010	325,781,294		17,328,284
05 Jul 2010	Share issue	800,000	0.020	16,000
15 Nov 2010	Share issue	3,466,669	0.025	86,667
16 Nov 2010	Exercise of converting note options	12,756,526	0.015	197,726
15 Dec 2010	Exercise of options	750,000	0.030	22,500
10 Jan 2011	Exercise of converting note options	8,130,081	0.025	200,000
01 Feb 2011	Exercise of converting note options	8,130,081	0.024	198,546
01 Apr 2011	Exercise of converting note options	5,000,000	0.020	100,000
13 Apr 2011	Share issue	4,000,000	0.039	156,000
14 Apr 2011	Exercise of converting note options	14,473,684	0.019	275,000
09 Jun 2011	Exercise of converting note options	9,345,794	0.021	200,000
	Closing balance 30 June 2011	392,634,129		18,780,723

Ordinary shares

No limit has been set on the total number of ordinary shares that the Company may issue. The ordinary shares do not carry par value.

Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the Company in proportion to the number of and amounts paid on the shares held.

On a show of hand every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote.

Notes to the Financial Statements

Continued

NOTE 19: CONTRIBUTED EQUITY (CONTINUED)

d. Movement in options

Date	Details	Consolidated Group	
		Number of options	\$
	Opening balance 1 July 2009	18,099,995	57,989
07 Jul 2009	Options issued	5,002,006	-
31 Dec 2009	Options issued	9,000,000	-
01 Jun 2010	Options lapsed	(3,000,000)	-
30 Jun 2010	Options issued	3,600,000	-
	Closing balance 30 June 2010	32,702,001	57,989
	Opening balance 1 July 2010	32,702,001	57,989
15 Nov 2010	Options issued	100,000	-
15 Dec 2010	Options exercised	(750,000)	-
	Closing balance 30 June 2011	32,052,001	57,989

On 15 November 2010, 100,000 share options were granted to employees with more than three years of full-time service under the Cellmid Limited employee option plan to take up ordinary shares at an exercise price of \$0.10 each. The options are exercisable on or before 15 November 2015. The options hold no voting or dividend rights and are not transferable.

The group has not granted any share options to the key management personnel in the financial year.

These options vested immediately on grant date. Further details of these options are provided in the directors' report. The options hold no voting or dividend rights but have been listed. The options lapse when a director ceases their employment with the group. During the financial year, no options vested with key management personnel (2010: 5,000,000).

NOTE 20: RESERVES AND ACCUMULATED LOSSES

a. Reserves

	Consolidated Group	
	2011	2010
	\$	\$
Share based payment reserve		
Balance 1 July	1,660,231	1,344,331
Option expenses	-	315,900
Balance 30 June	1,660,231	1,660,231
<i>Available for sale reserve</i>		
Balance 1 July	3,893	-
Revaluation	6,227	3,893
Balance 30 June	10,120	3,893
<i>Total reserves</i>		
Balance 1 July	1,664,124	1,344,331
Revaluation and options expenses	6,227	319,793
Balance 30 June	1,670,351	1,664,124

b. Accumulated losses

Movements in accumulated losses were as follows:

	Consolidated Group	
	2011	2010
	\$	\$
Balance 1 July 2010	(16,201,458)	(14,861,510)
Net income (loss) for the year	(2,269,637)	(1,339,948)
Balance 30 June 2011	(18,471,095)	(16,201,458)

Notes to the Financial Statements

Continued

NOTE 21: CASH FLOW INFORMATION

	Consolidated Group	
	2011	2010
	\$	\$
a. Reconciliation of Cash Flow from Operations with Profit after Income Tax		
(Loss) for the year	(2,269,637)	(1,339,948)
Non-cash flows in profit:		
– Depreciation and amortisation	10,256	13,721
– Share based payment	172,000	315,900
– Non-cash income	-	(50,000)
Changes in assets and liabilities, net of the effects of purchase and disposal of subsidiaries:		
– (increase)/decrease in trade and term receivables	7,064	5,287
– (increase)/decrease in prepayments	(8,981)	-
– (increase)/decrease in inventories	(97,182)	-
– increase/(decrease) in trade payables and accruals	(179,055)	(118,308)
– increase/(decrease) in provisions	36,812	5,909
Cash flow from operations	(2,328,723)	(1,167,439)

NOTE 22: CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that are believed to be reasonable under the circumstances.

a. Critical accounting estimates and assumptions

The group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

i. Estimated impairment of intellectual property

The group tests annually whether intellectual property has suffered any impairment, in accordance with the accounting policy stated in note 1. The recoverable amounts of the intellectual property have been determined based on reviewing the status of the research and development program, progress on its patent applications and projected cash flow calculations. These calculations require the use of assumptions.

NOTE 23: EVENTS AFTER THE REPORTING PERIOD

No matter or circumstance has arisen since 30 June 2011 that has significantly affected, or may significantly affect:

- The group's operation in future financial years
- The results of those operations in future financial years or
- The group's state of affairs in future financial years.

NOTE 24: RELATED PARTY TRANSACTIONS

Related Parties

a. The group's main related parties are as follows:

Parent entities:

Cellmid Limited is the ultimate parent entity within the wholly-owned group.

Subsidiaries:

For details of disclosures relating to subsidiaries, refer to Note 26: Controlled Entity.

Key management personnel:

For details of disclosures relating to key management personnel, refer to Note 6: Interests of Key Management Personnel (KMP).

b. Transactions with related parties:

Key management personnel:

The group has no other related party transactions occurred during the year ended 30 June 2011 other than the transactions outlined in Note 6.

Subsidiaries:

The transactions with the subsidiary have been eliminated on consolidation of the group.

Notes to the Financial Statements

Continued

NOTE 25: FINANCIAL RISK MANAGEMENT

Specific Financial Risk Exposures and Management

The group's activities expose it to a number of financial risks as described below. The group's overall risk management program seeks to minimise potential adverse effects on the financial performance of the group. To date, the group has not had the need to utilise derivative financial instruments such as foreign exchange contracts or interest rate swaps to manage any risk exposures identified.

The totals for each category of financial instruments, measured in accordance with AASB 139 as detailed in the accounting policies to these financial statements, are as follows:

	Note	Consolidated Group	
		2011	2010
		\$	\$
Financial assets			
Cash and cash equivalents	9	1,592,508	2,093,185
Loans and receivables	10	3,112	-
Available-for-sale financial assets:	12	60,120	53,893
Total financial assets		1,655,740	2,147,078
Financial liabilities			
Financial liabilities at amortised cost:			
– trade and other payables	16	133,705	312,760
– borrowings	17	556,835	-
Total financial liabilities		690,540	312,760

a. Credit risk

Credit risk is managed on a group basis. The group has no significant concentration of credit risk.

The maximum exposure to credit risk by class of recognised financial assets at the end of the reporting period is equivalent to the carrying value and classification of those financial assets (net of any provisions) as presented in the table above.

Trade and other receivables that are neither past due nor impaired are considered to be of high credit quality.

Credit risk related to balances with banks and other financial institutions is managed by the FRMC in accordance with approved board policy. Such policy requires that surplus funds are only invested with counterparties with a Standard & Poor's rating of at least AA-.

b. Liquidity risk

The group manages this risk through the following mechanisms:

- preparing forward-looking cash flow analysis in relation to its operational, investing and financing activities;
- managing credit risk related to financial assets;
- only investing surplus cash with major financial institutions

The group is not exposed to any material liquidity risk.

c. Market risk

Foreign exchange risk

Exposure to foreign exchange risk may result in the fair value or future cash flows of a financial instrument fluctuating due to movement in foreign exchange rates of currencies in which the group holds financial instruments which are other than the AUD functional currency of the group.

The group has no significant concentration of foreign exchange risk. The maximum exposure to foreign exchange risk is the fluctuation in the US dollar on the short term borrowings.

Price risk

The group is not exposed to any material price risk.

NOTE 26: CONTROLLED ENTITY

	Country of Incorporation	Percentage Owned (%)	
		2011	2010
Subsidiaries of Cellmid Limited			
Advangen International Pty Limited	Australia	100	100

* Percentage of voting power is in proportion to ownership

NOTE 27: SEGMENT INFORMATION

The primary business segment and the primary geographic segment within which the group operates are biotechnology and Australia respectively. For primary purposes, the entity operates in one business and one geographic segment as described.

NOTE 28: CONTINGENT LIABILITIES

a. Contingent liabilities

The parent entity and group had no significant contingent liabilities at 30 June 2011 or at 30 June 2010.

b. Contingent assets

The parent entity and group had no significant contingent assets at 30 June 2011 or at 30 June 2010.

NOTE 29: COMPANY DETAILS

The registered office of the company is: Level 6, 40 King Street, Sydney NSW 2000

The principal places of business are: Cellmid Limited Level 6, 40 King Street, Sydney NSW 2000
Advangen International Pty Limited Level 6, 40 King Street, Sydney NSW 2000

Directors' Declaration

The directors of the company declare that:

1. the financial statements and notes, as set out on pages 1 to 63, are in accordance with the Corporations Act 2001 and:
 - a. comply with Accounting Standards, which, as stated in accounting policy Note 1 to the financial statements, constitutes explicit and unreserved compliance with International Financial Reporting Standards (IFRS); and
 - b. give a true and fair view of the financial position as at 30 June 2011 and of the performance for the year ended on that date of the company and group;
2. the Chief Executive Officer and Chief Finance Officer have each declared that:
 - a. the financial records of the company for the financial year have been properly maintained in accordance with s 286 of the Corporations Act 2001;
 - b. the financial statements and notes for the financial year comply with Accounting Standards; and
 - c. the financial statements and notes for the financial year give a true and fair view; and
3. in the directors' opinion there are reasonable grounds to believe that the group will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the Board of Directors made pursuant to Section 295 (5) of the Corporations Act 2001.



Dr David King
Chairman

26th day of August 2011

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF CELLMID LIMITED

Report on the Financial Report

We have audited the accompanying financial report of Cellmid Limited, which comprises the statements of financial position as at 30 June 2011, the statements of comprehensive income, the statements of changes in equity and the statements of cash flows for the year then ended, notes comprising a summary of significant accounting policies, other explanatory information, and the directors' declaration of Cellmid Limited and the consolidated entity (the Group). The consolidated entity comprises the company and the entity it controlled at the year's end or from time to time during the financial year.

Directors' Responsibility for the Financial Report

The directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error. In Note 1, the directors also state, in accordance with Accounting Standard AASB 101 *Presentation of Financial Statements*, that the financial statements comply with *International Financial Reporting Standards*.

Auditor's Responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance about whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Tel: 61 2 9251 4100 | Fax: 61 2 9240 9821 | www.pkf.com.au

PKF | ABN 83 236 985 726

Level 10, 1 Margaret Street | Sydney | New South Wales 2000 | Australia

The PKF East Coast Practice is a member of the PKF International Limited network of legally independent member firms. The PKF East Coast Practice is also a member of the PKF Australia Limited national network of legally independent firms each trading as PKF. PKF East Coast Practice has offices in NSW, Victoria and Brisbane. PKF East Coast Practice does not accept responsibility or liability for the actions or inactions on the part of any other individual member firm or firms.

Liability limited by a scheme approved under Professional Standards Legislation.

Independence

In conducting our audit, we have complied with the independence requirements of the *Corporations Act 2001*.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of Cellmid Limited, would be in the same terms if given to the directors as at the time of this auditor's report.

Opinion

In our opinion:

- (a) the financial report of Cellmid Limited and the consolidated entity is in accordance with the *Corporations Act 2001*, including:
 - (i) giving a true and fair view of the company's and consolidated entity's financial position as at 30 June 2011 and of their performance for the year ended on that date; and
 - (ii) complying with Australian Accounting Standards and the *Corporations Regulations 2001*; and
- (b) the consolidated financial report also complies with *International Financial Reporting Standards* as disclosed in Note 1.

Report on the Remuneration Report

We have audited the Remuneration Report included on pages 16 to 20 of the directors' report for the year ended 30 June 2011. The directors of the company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

Opinion

In our opinion, the Remuneration Report of Cellmid Limited for the year ended 30 June 2011, complies with section 300A of the *Corporations Act 2001*.

**PKF**

Bruce Gordon
Partner

26 August 2011
Sydney

Additional Information

20 LARGEST SHAREHOLDERS AS AT 1 SEPTEMBER 2011

Holder Name	Balance	Percent
Cell Signals Inc	32,000,000	8.150
Mr Gregory Glenn Worth <Worth S/F A/C>	16,940,000	4.314
Haydos Corporation PTY LTD	15,000,000	3.820
Seistend Pty Ltd <DW King Super Fund A/C>	13,476,669	3.432
Talrind Pty Ltd <Worth D/T A/C>	5,569,865	1.419
Mr Christopher Walker	5,000,000	1.273
Mr Vincent Patrick Sweeney <Macguire Family Super A/C>	5,000,000	1.273
Ms Christine Anne Smith	4,897,588	1.247
Hera Investments Pty Ltd	4,700,000	1.197
Lee Geok Thye (Holdings) SDN BHD	4,500,000	1.146
Labirinto Pty Ltd	4,000,000	1.019
Mr Douglas Battersby & Mrs Alison Battersby <Veruse Employees S/F A/C>	4,000,000	1.019
VISTA Partners LLC	4,000,000	1.019
Mr Boonsri Pewkliang	3,200,000	0.815
Mrs Ellen Margaret Finger	3,000,000	0.764
Babaganoosh PTY LTD	3,000,000	0.764
Mrs Tania Hill	2,950,000	0.751
Mr Joshua Goldhirsch	2,500,000	0.637
Computer Skills Pty Ltd <Sunshine Super Fund A/C>	2,406,197	0.613
Chamier Endersbee Pty Ltd <Endersbee Family Super A/C>	2,200,000	0.560
Total	138,340,319	35.234
Issued Capital	392,634,129	

Distribution of shareholders

Holdings Ranges	Holders	Total Units	%
1-1,000	28	5,033	0.001
1,001-5,000	41	131,683	0.034
5,001-10,000	158	1,476,384	0.376
10,001-100,000	833	40,622,801	10.346
100,001-99,999,999,999	506	350,398,228	89.243
Totals	1,566	392,634,129	100.000

The number of security investors holding less than a marketable parcel of securities is nil.

Corporate Directory

Office

Level 6, 40 King Street
Sydney NSW 2000 Australia

Tel: +61 2 9299 0311

Fax: +61 2 9299 2198

Email: info@cellmid.com.au
www.cellmid.com.au

Non-Executive Chairman

David King

Chief Executive Officer and Managing Director

Maria Halasz

Non-Executive Director

Robin Beaumont

Company Secretary

Nicholas Falzon

Auditors

PKF Chartered Accountants
Level 10, 1 Margaret Street
Sydney NSW 2000 Australia

Solicitors

Piper Alderman
Governor Macquarie Tower
1 Farrer Place
Sydney NSW 2000 Australia

Patent Attorney

FB Rice & Co
Level 23, 44 Market Street
Sydney NSW 2000 Australia

Share Registry

Boardroom Limited
Level 2, 28 Margaret Street
Sydney NSW 2000 Australia





Cellmid Limited
Level 6, 40 King Street
Sydney NSW 2000
ABN 69 111 304 119

T: +61 2 9299 0311
F: +61 2 9299 2198
E: info@cellmid.com.au
www.cellmid.com.au

